Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
J Korean Med Sci. 2012 Jul;27(7):827-9. doi: 10.3346/jkms.2012.27.7.827. Epub 2012 Jun 29.
Although rare, intraoperative anaphylaxis can lead to significant morbidity and mortality. Aquafol® (Daewon Pharmaceutical Co. Ltd., Seoul, Korea), a microemulsion propofol, was developed to eliminate lipid solvent-related adverse events, and was used in clinical anesthesia since 2009 with little data about severe side effects such as anaphylaxis. A healthy 16-yr-old male patient who had past medical history with two previous operations of no complications developed cardiovascular shock with generalized erythema following administration of microemulsion propofol during anesthesia induction. Intravenous injection of epinephrine and steroid rescued him. He remained in a stable state without any problems postoperatively and was discharged. Clinicians should consider this rare but serious complication during induction of anesthesia with propofol.
尽管罕见,但术中过敏反应可导致严重的发病率和死亡率。Aquafol®(韩国 Daewon 制药有限公司)是一种微乳丙泊酚,旨在消除与脂质溶剂相关的不良事件,自 2009 年以来在临床麻醉中使用,关于严重副作用(如过敏反应)的数据较少。一名健康的 16 岁男性患者,既往两次手术无并发症,在麻醉诱导期间给予微乳丙泊酚后发生心血管休克和全身性红斑。静脉注射肾上腺素和类固醇后患者得到抢救。术后患者状态稳定,无任何问题,并已出院。在使用丙泊酚诱导麻醉时,临床医生应考虑这种罕见但严重的并发症。